The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 4 of the 31 sources its claims cite were checked for support.
Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.
Open accessAbstract
We report the 1-year results from one patient as the preliminary analysis of a first-in-human phase I clinical trial (ChiCTR2300072200) assessing the feasibility of autologous transplantation of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath for type 1 diabetes treatment. The patient achieved sustained insulin independence starting 75 days post-transplantation. The patient's time-in-target glycemic range increased from a baseline value of 43.18% to 96.21% by month 4 post-transplantation, accompanied by a decrease in glycated hemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level. Thereafter, the patient presented a state of stable glycemic control, with time-in-target glycemic range at >98% and glycated hemoglobin at around 5%. At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities. Promising results from this patient suggest that further clinical studies assessing CiPSC-islet transplantation in type 1 diabetes are warranted.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a first-in-human phase I trial (ChiCTR2300072200), a 25-year-old woman with 11-year type 1 diabetes received an autologous transplant of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath and achieved sustained insulin independence from day 75 post-transplantation. At 1 year, all study endpoints were met with no transplant-related abnormalities detected.
Key findings
- The patient achieved complete insulin independence on day 75 and remained insulin-independent through 1 year of follow-up; daily exogenous insulin had been 54 ± 0.9 units/day at baseline.
- Time-in-target glycemic range rose from a baseline of 43.18% to 87.18% at month 2 and 96.21% at month 4, and was >98% for 8 months by the 1-year endpoint; HbA1c fell from 7.57% at baseline to 6.50% at day 75 and 5.37% at day 120, remaining in the non-diabetic range (<5.7%) thereafter.
- Graft function: fasting C-peptide was undetectable at baseline, rose to 59.6–102.6 pmol/L by week 2, and plateaued at 407.1–721.6 pmol/L after insulin independence; BETA-2 score increased from 0.13 at baseline to 21.42 at day 75 and 41.83 at day 365. OGTT peak C-peptide was 1,847.0, 1,439.9, and 2,472.6 pmol/L at days 180, 270, and 365 (3.5-, 2.8-, and 3.4-fold over fasting).
- Safety: no treatment-emergent serious adverse events; treatment-emergent AEs were limited to the peri-transplantation period (puncture-site pain, nausea/vomiting from general anesthesia); no severe hypoglycemic events during follow-up; MRI (T2W-FS and T1W-FS) and tumor markers (β-HCG, AFP, CEA, CA125, CA15-3, CA19-9) showed no evidence of teratoma over 1 year.
Methods
- First patient of an ongoing first-in-human phase I trial (TJFCH-iPS-001; ChiCTR2300072200) evaluating safety, tolerability, and efficacy of autologous CiPSC islets in type 1 diabetes; primary endpoints were HbA1c <7.0% or a ≥1% decrease from baseline at 90–365 days, absence of severe hypoglycemic events, and safety/tolerability; secondary endpoints included insulin independence and stimulated C-peptide ≥0.3 ng/mL.
- Autologous CiPSCs were generated from the patient's adipose-derived mesenchymal stromal cells by a four-step small-molecule chemical reprogramming protocol (clone CiPSC-#8 selected from 23 colonies), then differentiated via a six-stage protocol into islet-like cells; release testing included dd-PCR for residual PSCs, WGS/WES, viability (98%), CHGA positivity (94.5%), and a glucose stimulation index of 1.37.
- 1,488,283 IEQ (19,843 IEQ/kg) were injected under ultrasound guidance into the abdominal anterior rectus sheath on June 25, 2023, across 7 injections; the patient continued existing immunosuppression (tacrolimus, mycophenolate mofetil, methylprednisolone) with basiliximab and etanercept induction. Outcomes were tracked by continuous glucose monitoring, HbA1c, C-peptide, OGTT, BETA-2 score, ultrasound/MRI, tumor markers, and autoantibodies.
Limitations
- Stated by the paper: safety and efficacy beyond 1 year and in more patients remain to be evaluated; the trial includes three patients total, and data from the second and third patients were not yet mature for reporting, so a larger cohort is warranted.
- Stated by the paper: the patient's pre-existing immunosuppression for a transplanted liver precluded evaluation of the recipient's immune response to the autologous graft, limiting insight into potential autoimmune response.
- Evident from the text: this is a single-patient report, so no control group or between-patient comparison is possible, and the concurrent immunosuppressive regimen (including basiliximab and etanercept induction) cannot be separated from the graft's contribution to the observed outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 31 cited sources checked · 4 supported · 0 flagged
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recently, we successfully reprogrammed human somatic cells to chemically induced PSCs (CiPSCs).”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Guan, J. ∙ Wang, G. ∙ Wang, J. ... Chemical reprogramming of human somatic cells to pluripotent stem cells Nature. 2022; 605:325-331 Crossref Scopus (178) PubMed Google Scholar source
- Supportedcites [5] 5. Liuyang, S. ∙ Wang, G. ∙ Wang, Y. ... Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming Cell Stem Cell. 2023; 30:450-459.e9 Full Text Full Text (PDF) Scopus (44) PubMed Google Scholar source
The Results report generating hCiPSCs from human somatic cells obtained from all 17 tested donors. The Results also describe tests confirming that the resulting cells meet the criteria for pluripotent stem cells. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thereafter, the patient presented a state of stable glycemic control, with time-in-target glycemic range at >98% and glycated hemoglobin at around 5%.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among them, 50 mice transplanted with the patient’s CiPSC-islets underwent histopathological analysis of major organs (heart, liver, spleen, kidney, lung, and brain) at the end of the observation period (Figure S2D), showing absence of graft-related malignancy even in high-dose transplantation experiments of up to 1 × 107 per mouse (Table S2).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Autologous CiPSCs were induced from adipose-derived mesenchymal stromal cells (ADSCs) isolated from the patient’s adipose tissue by chemical reprogramming as described previously.”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Guan, J. ∙ Wang, G. ∙ Wang, J. ... Chemical reprogramming of human somatic cells to pluripotent stem cells Nature. 2022; 605:325-331 Crossref Scopus (178) PubMed Google Scholar source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All safety and efficacy clinical endpoints were met at 1-year follow-up of the patient”
- Also stated in: § 1 Send email to zhongyangshen@vip.sina.com … Show more Show less · plain
“At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § 1 Send email to zhongyangshen@vip.sina.com … Show more Show less · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CiPSC-islet preparation met release criteria for transplantation, presenting uniform spheroids between 50–250 μm and scarlet dithizone staining (Figures S3A and S3B), a high viability of 98% (Figure S3C; Table S1, part 3), and a Chromogranin A (CHGA)-positive proportion of 94.5% of total cells (Figures S3D and S3E), of which 56.4% were C-peptide and NKX6.1-positive cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patient CiPSC-islets presented islet-sized aggregates containing approximately 60% β cells, 10% α-like cells, and 10% δ-like cells on average (Figures S1A–S1C).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prior to enrollment, the patient’s plasma C-peptide levels were below the limit of detection (6.6 pmol/L) under both fasting and glucose-challenged conditions.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within 2 weeks after transplantation, the patient’s daily exogenous insulin dose requirement began to reduce from baseline of 54 ± 0.9 units/day (Figure 2A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
- Probably not a substantial claim. 51
- It may state two separate claims as one. 54
- The quote only partly states this claim. 2
Every source the paper cites for this claim was checked and supports it.
In the paper
“the generation of CiPSCs from somatic cells employs abiotic, small-molecule chemicals as reprogramming factors that are easily manufactured and standardized, non-genome integrating, scalable, and fine-tunable.”
What the sources say
- Supportedcites [6] 6. Wang, J. ∙ Sun, S. ∙ Deng, H. Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives Cell Stem Cell. 2023; 30:1130-1147 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar source
The Introduction (passage 6; page not provided) describes small-molecule reprogramming factors as abiotic, easily manufactured and standardized, and non-integrative to the genome. It also calls chemical reprogramming suitable for scalable stem-cell generation and describes the process as controllable and tunable (passage 4). (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Different from conventional iPSCs, which are generated from somatic cells by genetic overexpression of transcription factors, the generation of CiPSCs from somatic cells employs abiotic, small-molecule chemicals as reprogramming factors”
What the sources say
- Supportedcites [6] 6. Wang, J. ∙ Sun, S. ∙ Deng, H. Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives Cell Stem Cell. 2023; 30:1130-1147 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar source
The Introduction describes conventional iPSC generation through forced expression of defined genes in somatic cells and contrasts TF-induced reprogramming with chemical reprogramming. It explicitly calls small molecules abiotic reprogramming factors and describes CiPSCs produced through chemical reprogramming. No page numbers are available in our copy. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The small molecules used in the chemical reprogramming approach offer ease of manufacture and standardization and are highly controllable, scalable, and cost-effective, which are important for standardized manufacturing of therapeutic cells.6”
What the sources say
- Supportedcites [6] 6. Wang, J. ∙ Sun, S. ∙ Deng, H. Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives Cell Stem Cell. 2023; 30:1130-1147 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CiPSC-islets were found to be glucose-responsive in vitro, with a glucose stimulation index of 1.37 (Table S1, part 3).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the 1-year endpoint, the patient’s TIR had been >98% for 8 months, a substantial improvement in comparison with the baseline TIR of 43.18% (Figure 2C).”
- Also stated in: § Discussion · plain
“ultimately achieving over 98% blood glucose TIR without exogenous insulin use”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The transplanted mice also showed restoration of glucose tolerance and glucose-responsive C-peptide secretion (Figures S2G and S2H).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pancreas graft was removed after a year due to severe thrombotic complications”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Her HbA1c level during the 2 years before enrollment was 7.40%–8.00%, higher than the American Diabetes Association (ADA)’s recommended target for T1D management (<7.0%).”
What the sources say
- Not matchedcites [29] 29. American Diabetes Association Professional, Practice Committee
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and a Chromogranin A (CHGA)-positive proportion of 94.5% of total cells (Figures S3D and S3E), of which 56.4% were C-peptide and NKX6.1-positive cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CiPSC-islet preparation also contained 13.4% glucagon-positive cells and 15.9% somatostatin-positive cells, as determined by flow cytometry and immunofluorescence staining (Figures S3D–S3J).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These transplantation experiments showed good survival of patient CiPSC-islets and an absence of teratoma formation or graft overgrowth (Figures S2A and S2B), including mice observed for an extended period of up to 58 weeks;”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A 25-year-old woman was diagnosed with T1D for 11 years (as of time of transplantation in 2023).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Her medical history included two liver transplantations due to cryptogenic cirrhosis in 2014 and 2016, respectively, and a whole pancreas transplantation in 2017 due to unstable glycemic control.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continuous glucose monitoring (CGM) measurements during the three months before transplantation showed severe glucose variability and endangerment by hypoglycemia”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prior to the clinical study, the patient CiPSC-islets were assessed in 244 immunodeficient mice in transplantation experiments, with no tumorigenesis observed in all transplanted mice (Table S2).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After insulin independence, the fasting C-peptide reached a plateau and fluctuated within a range of 407.1 to 721.6 pmol/L.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Her weight was 75 kg, and her body mass index was 27.3 kg/m2.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Based on assessments of panel reactive antibodies (PRAs), the patient was found to be PRA-positive for HLA-I and HLA-II antigens”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient was under regular immunosuppression for liver transplant maintenance.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite receiving intensive insulin treatment at a daily dose of 54 ± 0.9 units (mean ± SD) under the supervision of an endocrinologist, the patient was still not able to achieve target glycemic control.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After CiPSC-islet transplantation, the patient’s fasting serum C-peptide level, which was undetectable at baseline, increased promptly and reached levels ranging 59.6–102.6 pmol/L by the second week after transplantation (Figure 3A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This was consistent with single-cell RNA sequencing (scRNA-seq) analysis of the patient CiPSC-islets, which also showed ∼13% endocrine progenitor cells and ∼8% enterochromaffin-like cells (Figures S1D–S1F)”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“accompanied by a decrease in glycated hemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Her fasting glucose fluctuated greatly, with an average value of 210 ± 59 mg/dL (mean ± SD).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A TIR of 87.18% was achieved in the patient at month 2 post-transplantation, which increased to 96.21% at month 4 (Figure 2C).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The data showed that both transcripts were detected in CiPSC-islets at levels lower than the positive control and similar to the negative control, indicating that residual CiPSCs were not detected.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this patient, the transplantation area exhibited signal intensities comparable to the surrounding normal muscle tissue (iso-signal), indicating absence of abnormal fat accumulation (Figures 4I–4P).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Before transplantation, the patient suffered from long-term, hard-to-control diabetes complicated by episodes of severe hypoglycemia.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The blood glucose measurement at the 2 h time point was 155 mg/dL, which is below the diagnostic threshold for diabetes (≥200 mg/dL at 2 h).38”
What the sources say
- Not matchedcites [38]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“OGTT tests on days 180, 270, and 365 visits showed peak C-peptide levels of 1,847.0, 1,439.9, and 2,472.6 pmol/L, respectively, while the fold change in peak C-peptide values relative to the fasting C-peptide values was 3.5, 2.8, and 3.4, respectively (Figure 3D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The parallel C-peptide levels were 589.2 pmol/L in the fasting state and peaked at 2 h after glucose administration at 1,436.5 pmol/L, showing a 2.4-fold stimulation (Figure 3D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one. The quote only partly states this claim.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To improve glycemic control, the patient had previously received a pancreas transplantation in 2017, which had to be removed a year later due to thrombotic complications.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A slight elevation in glutamic acid decarboxylase antibody (GADA) level at one time point was observed.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Karyotype screen of the 23 clones with good morphology and normal cell growth showed abnormal karyotype in one, #11, which was removed from downstream screening.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, good-manufacturing-practice-compliant manufacture of personalized CiPSC-islets for autologous transplantation was conducted, allowing for the first report of clinical transplantation of CiPSC-derived cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Throughout follow-up, the patient was hospitalized one time for an upper respiratory tract infection and was discharged 5 days later.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient’s BETA-2 score increased steadily from a baseline value of 0.13 to 21.42 by the day 75 visit, with the most recent value of 41.83 at day 365 visit (Figure 3E)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin autoantibody (IAA), islet cell antibody (ICA), insulinoma-associated-2 antibodies (IA-2Ab), and zinc transporter 8 antibody (ZnT8) were consistently indicated as negative.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In addition, a whole pancreas transplantation was performed on May 4th, 2017, but the pancreas graft was removed one year later (August 8th, 2018) due to thrombotic complications.”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“From the day 180 visit, the patient’s glucose tolerance showed further improvement, showing relatively stable performance in OGTTs of subsequent visits thereafter (Figures 3B and 3D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment-emergent AEs were limited to the peri-transplantation period, which included pain at the puncture area and nausea and vomiting due to general anesthesia.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Before CiPSC-islets transplantation, the patient had undergone two liver transplants on July 8th, 2014 and September 27th, 2016, for liver cryptogenic cirrhosis.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the one with the highest cell yield was chosen for downstream manufacture (patient CiPSC-#8).”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the day 120 visit, the meal-responsiveness of C-peptide secretions was further improved, with a fasting level of 407.1 pmol/L and a 2-h postprandial level of 834.1 pmol/L.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this report, we present data from the clinical trial's first participant—a 25-year-old female with an 11-year history of T1D.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Subsequent T2W-FS images taken over the following 365 days after transplantation showed that the signal of the grafts remained consistent and stable in terms of location, shape, size, and magnetic resonance signal intensity, and the left abdominal rectus exhibited no signs of compression, displacement, or deformation, which together showed no indication of abnormal growth (Figures 4D–4H).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The average temperature was -196.2°C, with highest temperature at -190.7°C and lowest temperature at -196.4°C respectively.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“We found that transplantation to an extrahepatic site, underneath the abdominal anterior rectus sheath, led to superior CiPSC-islet survival and maturation, resulting in secretion levels of C-peptide (a marker of endogenous insulin secretion) and stimulation indices approaching those of non-diabetic humans.”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Liang, Z. ∙ Sun, D. ∙ Lu, S. ... Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets Nat. Metab. 2023; 5:29-40 Crossref Scopus (24) PubMed Google Scholar source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“we established a highly efficient, optimized differentiation protocol for the generation of islet-like cells from CiPSCs (CiPSC-islets), whose transcriptomic identity, composition, and insulin secretory function were comparable to that of native human islets.”
What the sources say
- Not checked yetcites [20] 20. Du, Y. ∙ Liang, Z. ∙ Wang, S. ... Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates Nat. Med. 2022; 28:272-282 Crossref Scopus (85) PubMed Google Scholar
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“with in-process quality control (QC) assessments throughout the manufacturing process.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was approved by the National Health Commission of the People’s Republic of China and the Medical Ethics Committee at Tianjin First Central Hospital.”
- Also stated in: § Author contributions · plain
“and was approved by the National Health Commission of the People’s Republic of China and the Medical Ethics Committee at Tianjin First Central Hospital”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Also stated in: § Author contributions · plain
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“indicating an increased risk of rejection and graft failure in the case of islet allotransplantation.”
What the sources say
- Not matchedcites [31]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [33]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient CiPSC-islet manufacturing process was subject to in-process QCs as shown in Table S1, part 2.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Systematic characterization of the selected patient CiPSC line used for downstream manufacture (patient CiPSC-#8) was performed, including trilineage differentiation potential and genomic stability assays.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings supported the viability of CiPSC-islet transplantation underneath the abdominal anterior rectus sheath, which led to relatively rapid restoration of insulin-independent glycemic control in the patient.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In vivo tumorigenicity tests prior to clinical transplantation of patient CiPSC-islets were performed on 50 immunodeficient SCID/Beige mice.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, an extrahepatic site was employed, which was a favorable option for this patient on account of her transplanted liver.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Non-synonymous mutations identified were shown below. The pathogenicity and/or carcinogenicity of these mutations was evaluated by screening of each genomic variants against the COSMIC Census, and their status in COSMIC databases and Clinvar databases, if any, was annotated in the right two columns.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Viability and yield were verified by trypan blue (Invitrogen, T10282) and Countess II Automated Cell Counter (Invitrogen, AMQAX1000).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The BETA-2 score, which used fasting metabolic variables, was derived and validated by Peter Senior, Shareen Forbes, and colleagues from individuals transplanted in the Edmonton Islet Transplantation Program and is widely used in the clinical assessment of graft function after islet transplantation.”
What the sources say
- Not matchedcites [69]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Firstly, safety and efficacy beyond 1 year and in more patients remain to be evaluated.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“while each 1% reduction of HbA1c toward the physiological level has been associated with a 21% reduction in risk of diabetes-related complications and death.52”
What the sources say
- Not matchedcites [52]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Follow-up with these patients is ongoing, as they were sequentially enrolled in accordance with regulatory safety requirements.”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“and was conducted in accordance to the Clinical Study Protocol (Data S1).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Whole-genome sequencing data and whole-exome sequencing data (WGS and WES) were generated for the patient’s ADSCs, CiPSC line, and the patient’s CiPSC-islets.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Flow cytometry was performed in dissociated cells for islet endocrine cell-related markers (NKX6.1, C-peptide, GCG, SST).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“During this time before transplantation, the items in Quality control and final check of CiPSC-islets preparation before transplantation (as shown in Table S1 Part 3) were tested as a final check.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The current patient provided written informed consent to undergo the procedure.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Secondly, the use of immunosuppressants in this patient precluded the evaluation of immune response of the recipient to the autologous graft.”
- Also stated in: § Discussion · hedged
“but insight into potential autoimmune response was limited.”
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Discussion · hedged
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, due to the limited follow-up period and according to our clinical trial protocol, data from these two patients are not yet matured for reporting.”
Strength:plain· not yet calibratedn = 2Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these findings indicate the feasibility of chemically induced autologous PSCs for cell therapy, constituting a viable personalized medicine strategy.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Glucose stimulated insulin secretion (GSIS) assay was conducted to evaluate the Glucose Stimulation Index (GSI) of functional potency.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“In comparison to intraportal transplantation, the abdominal rectus sheath site also encompasses other safety considerations, such as ease of access for transplantation and imaging and site retention of graft.21”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Liang, Z. ∙ Sun, D. ∙ Lu, S. ... Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets Nat. Metab. 2023; 5:29-40 Crossref Scopus (24) PubMed Google Scholar source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“For the CiPSC induction, a four step chemical reprogramming protocol without genetic manipulation was applied to patient ADSCs as described previously.4”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Guan, J. ∙ Wang, G. ∙ Wang, J. ... Chemical reprogramming of human somatic cells to pluripotent stem cells Nature. 2022; 605:325-331 Crossref Scopus (178) PubMed Google Scholar source
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the viability of CiPSC-islets was tested by fluorescein diacetate (FDA) / propidium iodide (PI) staining.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“CiPSC-islet cell recovery and preparation was conducted at the clinical site under GMP-level conditions.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial is ongoing and includes three patients in total.”
Strength:plain· not yet calibratedn = 3Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Data from another clinical trial (NCT04786262), which transplanted hPSC-derived islets into the hepatic portal vein, were recently announced, the findings of which also indicated positive outcomes post-transplantation.60”
What the sources say
- Not matchedcites [60]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Short tandem repeat (STR), whole genome sequencing (WGS) and whole exome sequencing (WES) tests were conducted on the selected clone #8, which passed all the tests.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together with our preclinical studies, the clinical data in this report support the clinical value of this transplantation strategy, warranting continued exploration.”
Tests✓ Asserted: passes? Checkable: unclear✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient CiPSC-#8 cell line was assessed for quality according to the requirements in Table S1 Part 1.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the Declaration of Helsinki”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Thorough testing of the final CiPSC-islets was conducted to detect for residues of concern, including residual BSA and cytokines.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“C-peptide measures taken in parallel showed undetectable C-peptide levels (Figure 3D), indicating a complete destruction of β cells and poor glucose tolerance.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, mycoplasma contamination, sterility and endotoxin levels were checked according to protocols in the Chinese pharmacopoeia (2020 version).”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The reagents used in the entire manufacturing process was subject to reagent controls, including checking documentation of certificates of analysis (COA) of every reagent.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Prior to the start of patient recruitment, the trial was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2300072200).”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We performed droplet digital PCR (dd-PCR) to verify biosafety of patient CiPSCs-islets.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these results indicated good graft function of the transplanted CiPSC-islets and recovery of endogenous, glucose-responsive insulin secretion in the patient.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All of the mouse experiments performed were approved by the Institutional Animal Care and Use Committee of Peking University.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The extraperitoneal transplant site has minimal invasiveness of injection and ease of imaging.
“Other important advantages of this self-contained extraperitoneal transplant site include minimal invasiveness of injection at the site and ease of imaging.”
The paper relies on this without support.
The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
“After CiPSC-islet transplantation, the patient achieved insulin independence within 3 months post-transplantation, ultimately achieving over 98% blood glucose TIR without exogenous insulin use.”
The paper relies on this without support.
The absence of tumorigenicity observed in mice and nonhuman primates predicts the absence of tumorigenicity in the human patient.
“Prior to the clinical study, the patient CiPSC-islets were assessed in 244 immunodeficient mice in transplantation experiments, with no tumorigenesis observed in all transplanted mice (Table S2).”
The paper relies on this without support.
The patient’s immunosuppressive maintenance regimen did not confound the glycemic or graft-function outcomes attributed to the CiPSC-islet transplant.
“the immunosuppressive maintenance regimen included tacrolimus, mycophenolate mofetil, and methylprednisolone tablets, which were continued after CiPSC transplantation”
The paper relies on this without support.
The abdominal anterior rectus sheath site is safe and effective for stem-cell-derived islet transplantation in humans based on preclinical studies.
“The positive metabolic data seen in this clinical study are consistent with that seen in our preclinical study in nonhuman primates, in which we sought to identify an optimal transplant site for CiPSC-islets.21”
The paper relies on this without support.
Type 1 diabetes is an autoimmune disease.
“Because T1D is an autoimmune disease”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicate that current technology can produce stemcell derived β cells capable of reversing type 1 diabetes (figure 2).”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In this study, the cells were transplanted into the rectus sheath in the anterior abdominal wall (table 3).72”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“These induced pluripotent stem cells were generated by chemical reprogramming of the cells using small molecules to dedifferentiate the cells rather than genetic methods.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Another landmark event in type 1 diabetes treatment was the reversal of diabetes with β cells derived from autologous induced pluripotent stem cells in a recipient with previous liver transplantation and therefore on immunosuppression.72”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Although stemcell therapy has shown remarkable results in a few people, 71,72 its promise as a therapy for broad application is dependent on the safe engineering of cells that avoid both alloimmunity and autoimmunity, and on production methods that meet the global demand for cellbased therapy at affordable costs.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Cryopreserved cells per vial differ between preparation and thawing
MajorThe stated cryopreservation concentration and 4 mL aliquot give 1.2 × 10^8 cells per vial, but the thawing procedure says each vial contained 1.8 × 10^8 cells.
“On day 0, 40 cryopreserved vials of CiPSC-islet cells (1.8 × 108 cells per vial) were thawed in a 37 °C water bath.”
“cells were suspended at 3 × 107 cells/mL in cryopreservation medium (5% dimethylsulfoxide (DMSO) (Sigma-Aldrich, D2650), 60% stage 6 medium, 35% FBS and 10 μM Y27632). Then, a 4 mL cell suspension was aliquoted into 5 mL vials.”
Claim of no added immunosuppression conflicts with induction therapy
MinorThe paper says the transplantation did not add to the patient's immunosuppression burden, but it also reports giving basiliximab as induction therapy in addition to her existing maintenance regimen.
“this allowed the assessment of therapeutic capacity of CiPSC-islets without adding to the patient’s immunosuppression burden”
“For CiPSC-islets transplantation, Basiliximab (20 mg) was used for induction therapy on day 0 and day 4.”
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Dictionary learning for integrative, multimodal and scalable single-cell analysis
Hao, Y., Stuart, T., Kowalski, M. H., Choudhary, S., Hoffman, P., Hartman, A., Srivastava, A., Molla, G., Madad, S., Fernandez-Granda, C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01767-y · Cited by 5,631
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells
D’Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O., Agulnick, A. D., Smart, N. G., Moorman, M. A., KROON, E. J., Carpenter, M. K., & Baetge, E. E. (2006) · Nature Biotechnology · doi:10.1038/nbt1259 · Cited by 1,913
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 281
Kumar, H., Kumari, R., Maurya, V. K., Amar, S. K., Ansari, P., Seidel, V., Harper, J., Kothari, A., Misra, A., & Kumar, S. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103420 · Cited by 3
Wei, Q.-S., Xing, Q.-Y., Ma, Y.-H., Zhang, K.-J., Ma, W., Zhang, M., Shi, H.-J., Peng, L., WANG, J.-H., Hu, Q.-X., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.177575 · Cited by 3
Sang, X., Xu, J., Wang, Y., Li, J., Xu, J., Chen, X., Shi, X., & Wu, F. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04120-5 · Cited by 3
Yan, P., Guo, Y., Muhammad, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-85674-z · Cited by 3
Illuminating the future of diabetes treatment: Autologous CiPSC-derived islets take center stage
Lou, Y. (2025) · Cell Transplantation · doi:10.1177/09636897251366828 · Cited by 3
Replacement of Beta Cells for Type 1 Diabetes
Herold, K. C., & Pober, J. S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2507578 · Cited by 3
Predictive control of human pancreatic cell fate using a digital model of in vitro differentiationPreprint
Sanchez-Castro, E. E., Ishahak, M., Le, T., Maestas, M. M., Hernandez-Rincon, D. C., Mukherjee, N., Bradley, K., Lu, J., Gale, S. E., & Millman, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.721124 · Cited by 4
Transplantation of Islet Organoids into Brown Adipose Tissue in a Diabetic Mouse Model
Sun, A., Singh, M., Bamrah, M., Li, W., Aguirre, A., & Wang, P. (2024) · Methods in molecular biology · doi:10.1007/7651_2024_588 · Cited by 2
Reprogramming of Different Cell Lineages into Functional β-Cell Substitutes
Dattoli, A. A., Kelemen, Y., & Huang, X. (2025) · Cellular Reprogramming · doi:10.1089/cell.2024.0102 · Cited by 3
“In this sense, reprogramming strategies offer a potential solution with autologous transplantation (Wang et al., 2024).”
Li, C., Wang, S., Jiang, J., Fu, W., & Zeng, J. (2025) · Biochimie · doi:10.1016/j.biochi.2025.07.011 · Cited by 2
Self-citationPancreatic injury induces β‐cell regeneration in axolotl
Powell, C. J., Singer, H. D., Juarez, A. R., et al. (2025) · Developmental Dynamics · doi:10.1002/dvdy.70060 · Cited by 2
Navigating challenges in human pluripotent stem cell-derived islet therapy for type 1 diabetes
Usama, M., Deng, Y., Chen, Y., Milland, T., Malleshaiah, M. K., & Aghazadeh, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625439 · Cited by 4
Advances and future perspectives in the treatment and prognosis of type 1 diabetes mellitus
Fu, Y., Zeng, J., & He, Q. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1651061 · Cited by 2
Erbasan, E., Aliciaslan, M., Erendor, F., Dandin, Ö., & Şanlıoğlu, S. (2025) · Diabetic Medicine · doi:10.1111/dme.70168 · Cited by 2
“40 Efforts are also directed towards optimizing islet engraftment, survival, and revascularization.”
Towards insulin independence in type 1 diabetes: Prospects for prevention and cure
Sydney, G. I., Perdigoto, A. L., & Herold, K. C. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004813 · Cited by 2
“In 2024, Wang and colleagues reported the clinically successful transplant and insulin independence of iPSC derived islets from a patient with T1D back into the same patient (autologous transplantation) [12].”
Kawai, K., Doğan, F., Alagpulinsa, D. A., Pop, R., Veres, A., Sobell, D., Deng, H., Collins, S. H., Zhang, J., Chapin, M. H., et al. (2025) · Xenotransplantation · doi:10.1111/xen.70098 · Cited by 2
Self-citationFu, X., Peng, F., Cai, R.-Y., Mao, J., Liu, T., Dong, Y., Cheng, R.-Q., Yang, Z., Chen, G.-X., Li, C., et al. (2025) · Cell Discovery · doi:10.1038/s41421-025-00852-7 · Cited by 2
Self-citationWaris, S., Begam, H. H., Kumar, M. P., Abdulrasool, Z., Avudaiappan, M., Butler, A. E., & Nandakumar, M. (2026) · Cells · doi:10.3390/cells15020191 · Cited by 6
“This marks the first report of clinical use of CiPSC-derived islets for the treatment of T1D [171].”
Type 1 Diabetes and Islet Encapsulation: From Historical Milestones to Cutting-Edge Advances
Mukherjee, S., Mandal, S., Oberholzer, J., & Omid Veiseh, A. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110824-024435 · Cited by 2
Thymus regeneration therapies: entering a new era
Kreins, A. Y., & Weinacht, K. G. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.03.005 · Cited by 2
Modeling immune responses to autologous and allogeneic human stem cell–derived islet grafts in vivo
Genzano, C. B., Zanetti, G., Du, Traum, D., Lahori, D., Downes, G. M., Bhatele, S., Ding, X., Apley, K. D., Firdessa-Fite, R., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.200738 · Cited by 2
“They not only provide a potential solution for replacing β cells lost in patients but also enable the generation of autologous (patient-specific) β cells, thereby avoiding alloimmune rejection (6, 7).”
Self-citationRegenerative macrophages enhance stem cell–derived β cell function and engraftment
Freitas, B. F. A., Fox, S. A., Orban, P. C., Velghe, J., Mojibian, M., Dai, D., Soukhatcheva, G., Lynn, F. C., Levings, M. K., & Verchere, C. B. (2026) · Science Advances · doi:10.1126/sciadv.aed4221 · Cited by 3
“SC-β cell–based replacement therapy has already entered clinical testing, with promising initial results ( 16 – 18 ).”
Engineering the future of advanced therapy medicinal products: a bioengineering call to action
Nieri, G., Spiller, A., Stella, F., Aiuti, A., & Piemonti, L. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1868007 · Cited by 2
Reversing Diabetes With Your Own Cells: Closer to the Dream
Genosar, R., Coman, M., & Herold, K. C. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae851 · Cited by 2
Advancing diabetes treatment: from human beta cell technology to bioartificial pancreas development
Sá, J., Sá, S. C., Leménager, H., Costa, R., Onteniente, B., Soares, R. A., Ribeiro, V. P., & de Oliveira, A. L. F. (2025) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2025.1524518 · Cited by 5
Gouw, B. H. T., Oliveira, F. C. M., Kooistra, H. S., Spee, B., van Uden, L., & Penning, L. C. (2025) · Veterinary Sciences · doi:10.3390/vetsci12040362 · Cited by 2
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“…treatment, particularly in the form of more comfortable drugs for patients, will likely differ significantly from current standards unless the transplantation of induced pluripotent stem-cell-derived islets becomes possible in a larger group of patients following the recent one-case success [6].”
InfluentialPancreatic islet organoids and organoids on-chip for type 1 diabetes
Mehanović, M., Lopes, M., Coffy, S., Pitaval, A., Freida, D., Gidrol, X., & Tubbs, E. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104302 · Cited by 2
Developing Stem Cell Therapy for Type 1 Diabetes Mellitus
Calafiore, R. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70079 · Cited by 2
“A true innovation in the field came from China, where transplant of chemically‐induced pluripotent stem cell‐derived islets in a patient with T1D, resulted in insulin independence at 1 year post transplant (ChiCTR2300072200) [12].”
Endocrine-enriched stem cell-derived islets improve long-term safety in vivoPreprint
Setyono, E. S. A., Rogers, N. K., Scheibner, K., Schirge, S., Reich, H., Sterr, M., Öztürk, T., Franzenburg, S., Lithovius, V., & Lickert, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.22.671768 · Cited by 2
“With the successful generation of glucose-responsive SC-islets, clinical trials have been performed, from transplanting pancreatic progenitor cells 25–27 to fully differentiated SC-islets 28,29 .”
Cell therapy for type 1 diabetes: Tracing historical progress and exploring emerging technologies
Perrier, Q., Lablanche, S., & Benhamou, P. (2025) · Cell Transplantation · doi:10.1177/09636897251394787 · Cited by 3
“A handful of two cases have emerged: one involving a young woman with T1D and prior organ transplants 10 , and another in a man with longstanding type 2 diabetes 11 .”
Autologous stem-cell derived islets — the ultimate frontier in diabetes mellitus?
Shapiro, A. M. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01064-x · Cited by 1
Chu, S. N., Stock, P. G., & Gardner, J. M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.11.005 · Cited by 1
Kamińska, M., Jasiewicz, M., Miernik-Skrzypczak, M., Spyra, A., Malicka, M., Dąbrowska, N., Kozioł, A., & Moczyróg, K. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57420 · Cited by 1
“Moreover, no or only minor, insignificant adverse effects were reported during those studies [7, 10, 11, 12, 13, 14].”
Na+/K+-ATPase: a multifunctional target in type 2 diabetes and pancreatic islets
Mou, L., Fu, Z., Wang, T. B., Chen, Y., Luo, Z., Wang, X., & Pu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1555310 · Cited by 1
Self-citationAdvancing type 1 diabetes treatment: a breakthrough in stem cell therapy.
Anfaal, Z., & Khan, Z. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101635 · Cited by 1
Wong, A., & Alejandro, E. U. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1562646 · Cited by 3
Yu, T. T., Mukuba, D., Casabar, M., Byrne, C., Shlomowitz, A., Jacob, P., Huda, M. S. B., Yaqoob, M. M., & Chowdhury, T. A. (2025) · Diabetic Medicine · doi:10.1111/dme.70075 · Cited by 1
Nguyen, K. M., Che, Q. T., Nguyen, Q. H., Gwon, K., Gonzalez‐Suarez, A. M., Stybayeva, G., Huebert, R. C., Peterson, Q. P., & Revzin, A. (2025) · Biomaterials Science · doi:10.1039/d5bm00696a · Cited by 1
Adrenocortical organoids: A promising tool for modelling human physiology and translational research
Tedesco, M., Schedl, A., & Neirijnck, Y. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104300 · Cited by 1
Wang, L., Yu, Z., Zhang, Y., Yang, Z., Zhao, J., Kong, D., & Wang, Y. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102849 · Cited by 1
The type 1 diabetes mellitus treatment
Morozov, A. M., Tsvetkova, A., Penyaz', E. V., Sitnova, V. A., & Smyslova, A. Y. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202528081131 · Cited by 1
From β soloist to endocrine symphony: Subtype-complete islets conduct glucose harmony
Zhao, J., Liang, S., & Kieffer, T. J. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.08.001 · Cited by 1
Twenty years of progress in type 1 diabetes mellitus
Kay, T. W. H., & Couper, J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01177-x · Cited by 1
“Two groups have reported the ability to reverse T1DM with fully differentiated human islet cells derived either from embryonic stem cell lines 5 or from autologous induced pluripotent stem cells 6 .”
Zhang, Q., Chen, H., Cun, J., Liu, Q., Wang, H., Jiang, L., Hu, S., Wang, H., Wang, J., Xu, J., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04831-3 · Cited by 1
“Human pluripotent stem cells (hPSCs) can self-renew indefinitely and differentiate into any cell type in the body, making them highly versatile for developing therapies to treat various diseases [1, 2]. hESCs, a type of hPSCs, are directly derived from early-stage embryos.”
Self-citationJeyagaran, A., & Schenke‐Layland, K. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115766 · Cited by 1
Biard, L., Lévy, V., Chevret, S., Künkele, A., Grunwald, S., Aiuti, A., Møller, B. K., Debets, R., Mielke, S., Eldere, J. V., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201651 · Cited by 1
Mosloflavone induces pancreatic α cells transdifferentiation into β cells through PDX1
Deng, L., Deng, T., Deng, Y., et al. (2025) · Journal of Natural Medicines · doi:10.1007/s11418-025-01995-3 · Cited by 1
Self-citationSimultaneous kidney and pancreas transplantation: Current trends and challenges
Alquadan, K., Belal, A., Mehta, R. V., Leghrouz, M., Ibrahim, H., Vrakas, G., & Santos, A. (2026) · World journal of transplantation · doi:10.5500/wjt.v16.i1.111064 · Cited by 1
“…induced pluripotent stem cell (iPSC) derived beta cells, have found long-term success for a select patient with T1DM as part of a clinical study in achieving sustained insulin independence of over a year can help overcome the limited supply of islet cells derived from deceased donor pancreas[50].”
Explainable reinforcement learning for glucose monitoring based on shapley value analysis
ADJEVI, A., Abdirashid, A. M., Aktaş, F., Uçar, M. H. B., & Solak, S. B. (2026) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2026.109266 · Cited by 1
Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy
Speight, J., Hussain, S., Anandhakrishnan, A., Danne, T., Latres, E., Karpen, S. R., Mytkolli, L., Scibilia, R., Soeholm, U., Senior, P. A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04201-3 · Cited by 1
Zamarian, V., Monaco, L. C., Marras, M., Ceriani, C., Pellegrini, S., Piemonti, L., & Sordi, V. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11091-y · Cited by 1
Bennett-Brown, H. A., Willemsen, N., Yuan, Y., Kranck, A. N., & Sancho, R. (2026) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2026.102466 · Cited by 1
Pasquetti, G., Thévenet, J., Chetboun, M., de Graaf, N., Carlotti, F., de Koning, E. J. P., Amassogo, C. A., Vandel, J., Ramos-Rodríguez, M., Pasquali, L., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aed3562 · Cited by 3
Rao, J. S., Barra, J. M., Parmentier, C., Chaudhry, A., Doherty, D. T., Komatsu, H., Mitsugashira, H., Citro, A., Nijhoff, M. F., Piemonti, L., et al. (2026) · Transplantation · doi:10.1097/tp.0000000000005710 · Cited by 1
Stammzell- und Betazell-Transplantation bei Diabetes mellitus
Ludwig, B. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2532-2007 · Cited by 1
Li, Z., Kang, Y., & Niu, Y. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70211 · Cited by 1
“60–63 In 2020, Wang et al. 64 identified a Procr-expressing cell population as adult islet stem cells within mouse pancreatic islets.”
From architecture to function: mechanisms shaping pancreatic islet morphogenesis
den Bosch, M. M. V., Greisle, T., Karampelias, C., & Lickert, H. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.04.009 · Cited by 1
Structure Variations and 3D Genome Disruption: Implications in Safety of hPSC-Based Cell Therapy
Li, M., Cui, F., Na, T., Ma, Q., Guo, M., Guo, M., Zhang, K., & Meng, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104573 · Cited by 1
“Furthermore, chemically induced pluripotent stem cell-derived islets have also achieved a functional cure for type 1 diabetes [15].”
Landscape of advanced therapy medicinal products in China and future trends
Yin, H., Meng, W., Wei, X., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3291-8 · Cited by 1
“Other ap-3332 proaches also show distinct advantages: small molecules used in chemical reprogramming are easily manufactured and scalable, providing a robust route to generate therapeutic-grade pluripotent stem cells (Wang et al., 2024).”
Pancreatic tissue engineering: towards a vascularized bioengineered cure for diabetes
Park, J., Olawuyi, K., Jikaria, N. R., Dawes, J. S., Dabsha, I. E., Dick, A. A., & Ravnic, D. J. (2026) · Frontiers in Transplantation · doi:10.3389/frtra.2026.1768497 · Cited by 1
“The impact of this approach was demonstrated through the transplantation of CiPSC-derived islets into individuals with T1D under immunosuppression, resulting in sustained insulin independence and improved glycemic control (72).”
Engineering early immune resilience in islet transplantation
Li, Y., Gasaly, N., Lakey, J. R. T., et al. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.05.006 · Cited by 1
Stem cell therapies for treatment of diabetes mellitus
Guo, F., Song, Y., & Qin, G. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004150 · Cited by 1
“Deng et al [72] transplanted CiPSC-generated islets into a T1DM patient via implantation beneath the anterior rectus sheath.”
InfluentialChina’s investigator-initiated trials in cell and gene therapy
Sun, X., Jia, H., Qian, F., et al. (2026) · Vita · doi:10.15302/vita.2026.06.0048 · Cited by 1
A multi-centre study of belatacept and sirolimus for islet transplantation
Rogers, N. M., Hu, M., Jimenez‐Vera, E., Gabor, H., Sharma, P., Etherton, C., Loudovaris, T., Hawthorne, W. J., Drogemuller, C., Torpy, D. J., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06813-3 · Cited by 1
“Until a less restricted source of donor islets is readily available, through allogeneic [30] or autologous chemically induced pluripotent [31] stem-cell-derived beta cells, the focus will remain on optimising immunosuppression to improve islet function.”
Hypoimmune platforms: from rejection to immune evasion and regulatory implications
Campo, F., Bellini, M. I., Scholz, H., Piemonti, L., & Citro, A. (2026) · Transplant International · doi:10.3389/ti.2026.16845 · Cited by 1
“However, in these cases, recipients required systemic immunosuppression due to allogeneic nature of the graft or prior organ transplants, masking the true immune response and highlighting the substantial challenge of achieving durable engraftment in immunocompetent patients [49].”
Gasiūnaitė, A., Tihaya, M. S., van Amerongen-Westra, I. M., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.103084 · Cited by 1
Bal, T. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01919-y · Cited by 2
“In these reports, pilot/clinical studies showed glycemic control within 3–4 months showing the promise of this technology [331, 332].”
Sulaiman, S. A., Alaarag, A., Rayyan, N., Tuffaha, Y., Al‐Awamleh, N. A., & Dojan, K. A. A. (2025) · World Journal of Pediatrics · doi:10.1007/s12519-025-00908-4 · Cited by 1
“All safety and efficacy outcomes were also met at one-year follow-up with no indication of transplant-related abnormalities [56, 57].”
Fan, W., Taoxia, E., Lu, B., et al. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.04.064 · Cited by 1
SteMClass: A Novel DNA Methylation-Based Classifier for iPSC In Vitro Differentiation StatesPreprint
Pérez, E., Vallone, V. B. F., Teichmann, D., Euskirchen, P., Siewert, C., Osberg, B., Wolkenstein, P., Stachelscheid, H., & Capper, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.02.673063 · Cited by 1
Cyborg pancreatic islet organoids
Lang, J., & Raoux, M. (2026) · Science · doi:10.1126/science.aef2219 · Cited by 1
Sneaking Islets Into the Liver during Ex Vivo Normothermic Preservation
Shapiro, A. M. J. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006573
Xu, M., & Ning, G. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100743
Mottet, G., Grassart, A., Barthélemy, P., Antignac, C., Arrabal, S., BOURDIN, A. A., Descroix, S., Vos, J. D., Doutriaux, A., Fabrega, Q., et al. (2024) · Therapies · doi:10.1016/j.therap.2024.12.003
PLOS Biology and the life sciences in 2024
Routledge, D., & Editors, O. B. O. T. P. B. S. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002985
Lee, Y.-J., Lee, I.-W., Kim, T. H., et al. (2015) · Journal of Animal Reproduciton and Biotechnology · doi:10.12750/jarb.39.4.278
A Cure Within for Type 1 Diabetes: Stem Cell-derived Islet Transplantation
Agarwal, D., & Naji, A. (2025) · Transplantation · doi:10.1097/tp.0000000000005337
Benhamou, P. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.01.004
Teo, A. K. S., Tan, K. S. M., Koh, Y. X., Koh, A., & Teo, A. K. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00143-5
Research progress on chemical reprogramming for inducing human pluripotent stem cells
Cheng, L., & Deng, H. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0301
Self-citationScharfmann, R. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.011
Tunbridge, M. J., & Luo, X. (2025) · Transplantation · doi:10.1097/tp.0000000000005424
Kozlowski, P., Muthukumarasamy, K. M., Deshmukh, A., da Rocha, A. M., & Oral, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.23.655123
Stem Cell Therapy in Diabetes: Prospects and Challenges
Wang, X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au23386
Self-citationWürfel, M., & Ebert, T. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01331-z
10-1: EPIGENETIC REGULATION TO IMPROVE REGENERATION OF GLUCOSE-RESPONSIVE Β-LIKE CELLS
Al‐Hasani, K., Marikar, S. N., Kaipananickal, H., et al. (2025) · Transplantation · doi:10.1097/01.tp.0001123160.17466.da
Advances in Immunotherapy for Type 1 Diabetes
Wang, J. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/e7mf5w82
Research Progress on Pancreatic Islet Organoids
Tan, M., Li, G., Shen, N., Wang, X.-D., Du, X.-C., Zhang, L., & Zhang, H. (2025) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x383245250617052324
Self-citationStem cell-derived islets — significant progress amidst ongoing challenges for type 1 diabetes
Dong, L., Cao, X., Mi, C., Fu, H., & Liu, H. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100149
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Chen, A. R., Chansky, J., & Burke, J. A. (2025) · Frontiers in Transplantation · doi:10.3389/frtra.2025.1614849
Hope for diabetes: CRISPR-edited cells pump out insulin in a person — and evade immune detection
Dolgin, E. (2025) · Nature · doi:10.1038/d41586-025-02802-5 · Cited by 1
Shao, H. (2025) · American Journal of Stem Cells · doi:10.62347/yzan4747
He, H., Duan, S., He, B., et al. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01162-y
“Stem cells, as an emerging therapeutic option, have shown excellent performance in the treatment of spinal cord injury [43], heart failure [44], diabetes [45], tendon rupture [46] and other diseases.”
Stem cells for therapy of neurodegeneration
Полтавцева, Р. А., Svirshchevskaya, E. V., Tchikov, V. M., Bobkova, N. V., & Sukhikh, G. T. (2025) · Регенерация органов и тканей. · doi:10.60043/2949-5938-2024-3-14-32
Sekar, N. C., & Rogers, N. M. (2025) · Transplantation · doi:10.1097/tp.0000000000005526
Zhang, Q., Cui, L., Jia, Y., Shi, X., Zhang, J., Zhang, L., Liu, Z., Zhang, Y., Fu, H., Qi, Q., et al. (2025) · Stem Cells International · doi:10.1155/sci/3010753
“Notable clinical advancements have underscored this potential: in 2024, Deng ’ s group reported the fi rst successful transplantation of hiPSC-derived pancreatic islets into a patient with type 1 diabetes, who achieved complete insulin independence within 75 days [6].”
Self-citationNeue Therapieoptionen bei Diabetes mellitus Typ 1
Arndt, S. V. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00289-z
Lü, J., Kim, H., Zhu, J., Martin, C., Zhang, J., Polavarapu, V., Lacko, L. A., Ariyachet, C., Dattoli, A. A., Liu, T., et al. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102708
Self-citationWu, D., Gao, F., Dai, M., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004148
“Type 1 Diabetes: Small-scale studies using reprogrammed pluripotent stem cells to generate insulin-secreting islet cells have demonstrated temporary insulin independence in some patients following transplantation [9] .”
Metadata
- Authors
- Wang, S., Du, Y., Zhang, B., Meng, G., Liu, Z., Liew, S. Y., Liang, R., Zhang, Z., Cai, X., Wu, S., Gao, W., Zhuang, D., Zou, J., Huang, H., Wang, M., Wang, X., Wang, X., Liang, T., Liu, T., Gu, J., Liu, N., Wei, Y., Ding, X., Pu, Y., Zhan, Y., Luo, Y., Sun, P., Xie, S., Yang, J., Weng, Y., Zhou, C., Wang, Z., Wang, S., Deng, H., & Shen, Z.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Nankai University (CN)
- Corresponding author
- Wang, Shusen
- Deng, Hongkui
- Shen, Zhongyang
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2024-10
- Volume
- 187
- Issue
- 22
- Pages
- 6152-6164.e18
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4402843606
- Semantic Scholar
- 53d12206f7b2371dbe9f6cc2db7448dfa741cad5
- Cited by
- 281
- References
- 70
- Citations by year
- 2026: 120 · 2025: 143 · 2024: 17
- FWCI
- 117.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 395 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82070805, 32288102, 82100841, NKTM2023002)
- Tianjin Municipal Human Resources and Social Security Bureau (XB202011)
- Tianjin Municipal Science and Technology Bureau (22JCZXJC00110, 2023C03019)
- National Key Research and Development Program of China (2020YFA0803704)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- type 1 diabetes, islet transplantation, autologous transplantation, anterior rectus sheath, insulin independence, glycemic control, HbA1c
- MeSH terms
- Single-Case Studies as Topic, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Insulin, Islets of Langerhans, Male, Islets of Langerhans Transplantation, Rectus Abdominis, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
